Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.73B P/E 10.82 EPS this Y 103.70% Ern Qtrly Grth -
Income 9.21M Forward P/E 12.24 EPS next Y 62.50% 50D Avg Chg 3.00%
Sales 400.56M PEG 0.23 EPS past 5Y 6.41% 200D Avg Chg 1.00%
Dividend N/A Price/Book 2.45 EPS next 5Y 72.58% 52W High Chg -12.00%
Recommedations 2.00 Quick Ratio 3.60 Shares Outstanding 159.74M 52W Low Chg 14.00%
Insider Own 1.69% ROA 14.93% Shares Float 131.89M Beta 0.49
Inst Own 109.54% ROE - Shares Shorted/Prior 11.61M/14M Price 11.14
Gross Margin 67.95% Profit Margin 2.30% Avg. Volume 2,016,201 Target Price 11.43
Oper. Margin 29.07% Earnings Date Nov 7 Volume 821,302 Change -0.98%
About Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Ironwood Pharmaceuticals, Inc. News
12/20/24 Here’s Why Brown Capital Management Small Company Fund Sold Ironwood Pharmaceuticals (IRWD)
12/10/24 High Growth Tech Stocks In The United States To Watch
11/26/24 Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference
11/13/24 Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
11/08/24 Ironwood's Q3 Earnings Lag Estimates, Revenues Top, Stock Down
11/08/24 Ironwood Pharmaceuticals Inc (IRWD) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ...
11/07/24 Ironwood Pharmaceuticals (IRWD) Misses Q3 Earnings Estimates
11/07/24 Ironwood: Q3 Earnings Snapshot
11/07/24 Ironwood Pharmaceuticals Reports Third Quarter 2024 Results
10/28/24 Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024
10/24/24 Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call
10/16/24 State Street Corp's Strategic Acquisition of Ironwood Pharmaceuticals Shares
10/16/24 Is Ironwood Pharmaceuticals, Inc. (IRWD) the Penny Stock with the Biggest Upside Potential According to Analysts?
10/09/24 Ironwood Pharmaceuticals Inc (IRWD) Q2 2024 Earnings Call Highlights: Strong LINZESS Demand ...
09/17/24 Implied Volatility Surging for Ironwood (IRWD) Stock Options
09/01/24 Ironwood Pharmaceuticals, Inc. (IRWD): The Best Multibagger Penny Stock of 2025?
08/29/24 Ironwood Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
08/14/24 Analysts Have Just Cut Their Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Revenue Estimates By 13%
08/10/24 Ironwood Pharmaceuticals, Inc. Reported A Surprise Loss, And Analysts Have Updated Their Forecasts
08/09/24 Ironwood (IRWD) Q2 Earnings & Revenues Fall Shy of Estimates
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Emany Sravan Kumar SVP, Chief Financial.. SVP, Chief Financial Officer Sep 15 Buy 8.32 36,072 300,119 188,730 09/18/23
MCCOURT Thomas A Chief Executive Offi.. Chief Executive Officer May 30 Sell 10.70 26,632 284,962 758,284 06/01/23
Silver Ronald Principal Accounting.. Principal Accounting Officer Feb 27 Sell 11.36 5,978 67,910 98,491 03/01/23
Rickard Jason SVP, Chief Operating.. SVP, Chief Operating Officer Feb 27 Sell 11.36 34,175 388,228 332,648 03/01/23
MCCOURT Thomas A Chief Executive Offi.. Chief Executive Officer Feb 27 Sell 11.36 61,231 695,584 681,354 03/01/23
Shetzline Michael CMO,SVP,Head-Res&Dru.. CMO,SVP,Head-Res&Drug Feb 27 Sell 11.36 19,322 219,498 261,586 03/01/23
John Minardo Chief Legal Officer Chief Legal Officer Feb 27 Sell 11.36 6,697 76,078 133,738 03/01/23
Davis Andrew SVP, Chief Business.. SVP, Chief Business Officer Feb 27 Sell 11.36 3,573 40,589 151,396 03/01/23
Currie Mark G Director Director Aug 11 Sell 11.78 70,000 824,600 521,758 08/15/22
Rickard Jason SVP, Chief Operating.. SVP, Chief Operating Officer Aug 08 Sell 11.65 47,477 553,107 376,730 08/10/22
Rickard Jason SVP, Chief Operating.. SVP, Chief Operating Officer Aug 08 Option 11.65 18,041 210,178 394,771 08/10/22
Currie Mark G Director Director Jun 07 Option 11.65 190,383 2,217,962 782,141 06/09/22
Currie Mark G Director Director Jun 07 Sell 12.01 190,383 2,286,500 591,758 06/09/22
- - - Mar 10 Buy 10.42 225,000 2,344,500 16,390,000 03/10/21
DENNER ALEXANDER J Director Director Mar 02 Buy 9.45 1,350,000 12,757,500 15,390,000 03/02/21
Rickard Jason SVP, Chief Operating.. SVP, Chief Operating Officer Mar 02 Sell 9.11 13,651 124,361 306,682 03/02/21
MacDonald Kelly Chief Accounting Off.. Chief Accounting Officer Dec 08 Option 9.12 5,639 51,428 98,680 12/08/20
MacDonald Kelly Chief Accounting Off.. Chief Accounting Officer Dec 08 Sell 12.5 5,639 70,488 93,041 12/08/20
Kilroy Conor SVP, GC & Secretary SVP, GC & Secretary Nov 10 Sell 10.92 836 9,129 128,833 11/10/20
Consylman Gina SVP, CFO & Treasurer SVP, CFO & Treasurer Nov 10 Sell 10.92 1,415 15,452 269,699 11/10/20